France Anemia Drugs Market Analysis Report 2022 to 2030

France Anemia Drugs Market Analysis

$ 3999

France's Anemia drugs market was valued at 439 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.9% from 2022 to 2030 and will reach $807 Mn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies and the increase in chronic diseases. The market is segmented by type, drug, and distribution channel. Some key players in this market are Amgen, Aspen, AstraZeneca, Bristol Myers Squibb, Chiesi Farmaceutici, Curium, and Daiichi Sankyo Co.

ID: IN10FRPH008 CATEGORY: Pharmaceuticals GEOGRAPHY: France AUTHOR: Nandini Shah

Buy Now

France Anemia Drugs Market Executive Summary

The France Anemia drugs market was valued at 439 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.9% from 2022 to 2030 and will reach $807 Mn in 2030. Anemia is a medical condition in which the hemoglobin or red blood cell (RBC) count is lower than normal. Fatigue, shortness of breath, dizziness, and palpitations are some of the most prevalent signs and symptoms of Anemia. There are three types of anemia. Anemia is caused by excessive blood loss, which can occur during childbirth, menstruation, or RBC loss due to prolonged bleeding.

One factor driving the growth of the anemia drugs market in France is the increasing prevalence of anemia, particularly among elderly patients and those with chronic kidney disease. In addition, the development of new drugs and treatment options is expected to further boost the market in the coming years. According to the World Bank collection of development indicators derived from officially recognized sources, the prevalence of anemia among non-pregnant women (women aged 15-49) in France was reported at 10.4%and the prevalence of anemia among children (ages 6-59 months) was 40% in 2019.

Market Dynamics

Market Growth Drivers

Anemia is a common condition in France, especially among the elderly population and individuals with chronic kidney disease. The prevalence of anemia is expected to increase further in the coming years due to the aging population and rising incidence of chronic diseases. ESAs are widely used to treat anemia and stimulate the production of red blood cells. The demand for ESAs is expected to increase in France due to the growing prevalence of anemia and the increasing number of patients undergoing chemotherapy or kidney dialysis. Several new drugs and treatment options have been developed in recent years to treat anemia. These new options offer improved efficacy and safety profiles, which are expected to drive the growth of the anemia drugs market in France. There is growing awareness among patients and healthcare professionals about the consequences of anemia and the importance of timely and effective treatment. This is expected to increase the demand for anemia drugs and boost the market growth.

Market Restraints

The anemia drug market in France is highly competitive, with several pharmaceutical companies offering similar products. This competition can lead to pricing pressures and reduced profit margins, which can be challenging for companies operating in the market. Some anemia drugs, particularly erythropoiesis-stimulating agents (ESAs), have been associated with safety concerns, such as an increased risk of blood clots, stroke, and heart attack. These safety concerns have led to increased regulatory scrutiny and caution in prescribing these drugs. Pricing pressures are a major challenge for the anemia drug market in France, as the government and other payers are increasingly seeking to limit healthcare costs. This can lead to pricing pressures for drug manufacturers, making it difficult to maintain profitability.

Competitive Landscape

Key Players

AbbVie
Amgen
Aspen
AstraZeneca
Bristol Myers Squibb
Chiesi Farmaceutici
Curium
Daiichi Sankyo Co.
Ever Pharma
GlaxoSmithKline

Notable Deals

16 Feb 2023: Erytech Pharma and Pherecydes Pharma announced that they will merge their operations and relocate all personnel to Erytech's headquarters in Lyon, France, where they will benefit from a presence in a key European infectious illness hub.

Healthcare Policies and Regulatory Landscape

In France, the anemia drug market is regulated by the French National Agency for Medicines and Health Products Safety (ANSM) and the European Medicines Agency (EMA). The ANSM is responsible for regulating the safety, quality, and efficacy of medicines, including anemia drugs, in France. The agency reviews new drug applications and monitors the safety of approved drugs, and can take regulatory action if safety concerns arise. The EMA is responsible for the scientific evaluation and supervision of medicines in the European Union (EU), including anemia drugs. The EMA provides scientific advice to drug manufacturers, assesses marketing authorization applications, and monitors the safety of approved drugs in the EU.

In addition to ANSM and EMA, there are several other regulatory bodies that may impact the anemia drug market in France. For example, the French High Authority for Health (HAS) is responsible for assessing the clinical and economic benefits of new drugs and providing recommendations on reimbursement decisions to the French National Health Insurance Fund.

Reimbursement Scenario

In France, the reimbursement of drugs is governed by the French National Health Insurance Fund (CNAM), which operates under the oversight of the Ministry of Social Affairs and Health. The CNAM is responsible for setting the prices and reimbursement rates for all prescription drugs, including anemia drugs. The reimbursement of drugs in France is typically based on the recommendations of the French High Authority for Health (HAS). The HAS evaluates the clinical and economic benefits of new drugs and provides recommendations on whether they should be reimbursed by the CNAM.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Anemia Drugs Market Segmentation

By Type (Revenue, USD Billion):

Iron Deficiency
CKD (Chronic Kidney Disease)
Sickle Cell
Aplastic
Others

By Drugs

Dietary Supplements
Medicines

The types of nutritional supplements are further broken down into iron and vitamin supplements, among other categories, whilst the categories of medicines include antibiotics, hormones (erythropoietin), and chelation therapy (lead poisoning), among others.

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacy
Store Pharmacy
Online
Others

The distribution channel for anemia drugs in France is complex and multifaceted. Pharmaceutical companies must work with a variety of stakeholders, including hospital and retail pharmacies, distributors, and regulatory authorities, to ensure that their products are effectively distributed to patients who need them.

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.